Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Bought by International Assets Investment Management LLC

International Assets Investment Management LLC raised its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 11,244.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 66,935 shares of the medical equipment provider's stock after purchasing an additional 66,345 shares during the quarter. International Assets Investment Management LLC's holdings in Zimmer Biomet were worth $8,146,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. PFG Advisors raised its holdings in Zimmer Biomet by 4.6% in the fourth quarter. PFG Advisors now owns 1,899 shares of the medical equipment provider's stock worth $231,000 after purchasing an additional 84 shares in the last quarter. Quent Capital LLC increased its stake in shares of Zimmer Biomet by 21.6% during the fourth quarter. Quent Capital LLC now owns 518 shares of the medical equipment provider's stock valued at $63,000 after purchasing an additional 92 shares in the last quarter. Pinnacle Associates Ltd. lifted its holdings in shares of Zimmer Biomet by 5.0% during the third quarter. Pinnacle Associates Ltd. now owns 2,020 shares of the medical equipment provider's stock valued at $227,000 after purchasing an additional 97 shares during the last quarter. Financial Advocates Investment Management boosted its position in shares of Zimmer Biomet by 3.8% in the 3rd quarter. Financial Advocates Investment Management now owns 2,625 shares of the medical equipment provider's stock worth $295,000 after purchasing an additional 97 shares in the last quarter. Finally, Stokes Family Office LLC grew its stake in shares of Zimmer Biomet by 4.1% in the 3rd quarter. Stokes Family Office LLC now owns 2,498 shares of the medical equipment provider's stock worth $280,000 after buying an additional 99 shares during the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ZBH has been the topic of several analyst reports. Oppenheimer boosted their target price on Zimmer Biomet from $150.00 to $155.00 and gave the stock an "outperform" rating in a report on Friday. StockNews.com lowered shares of Zimmer Biomet from a "strong-buy" rating to a "buy" rating in a research note on Monday, February 19th. Citigroup upped their target price on shares of Zimmer Biomet from $134.00 to $140.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 3rd. Canaccord Genuity Group reissued a "hold" rating and set a $130.00 price target on shares of Zimmer Biomet in a research report on Friday, February 23rd. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $140.00 price objective on shares of Zimmer Biomet in a research report on Friday, February 9th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $135.40.

Insider Activity at Zimmer Biomet

In other Zimmer Biomet news, VP Chad F. Phipps sold 26,156 shares of the company's stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total value of $3,364,184.72. Following the completion of the sale, the vice president now owns 44,145 shares in the company, valued at $5,677,929.90. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 0.70% of the stock is owned by company insiders.

Zimmer Biomet Stock Performance

NYSE:ZBH traded up $0.87 on Tuesday, hitting $121.43. The stock had a trading volume of 1,334,998 shares, compared to its average volume of 1,478,998. Zimmer Biomet Holdings, Inc. has a 52-week low of $102.00 and a 52-week high of $147.50. The stock has a market cap of $24.98 billion, a price-to-earnings ratio of 26.28, a price-to-earnings-growth ratio of 2.23 and a beta of 1.03. The company has a quick ratio of 0.80, a current ratio of 1.66 and a debt-to-equity ratio of 0.38. The business's 50-day simple moving average is $125.07 and its two-hundred day simple moving average is $120.44.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.94 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.87 by $0.07. Zimmer Biomet had a net margin of 12.93% and a return on equity of 12.70%. The company had revenue of $1.89 billion for the quarter, compared to the consensus estimate of $1.87 billion. During the same quarter last year, the firm posted $1.89 earnings per share. The firm's revenue was up 3.2% compared to the same quarter last year. As a group, research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.1 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th were paid a $0.24 dividend. The ex-dividend date of this dividend was Wednesday, March 27th. This represents a $0.96 annualized dividend and a dividend yield of 0.79%. Zimmer Biomet's dividend payout ratio (DPR) is 20.78%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.